文献速递前列腺癌

PRIMARY2试验方案:多中心、3期随机对照试验,探讨[68Ga]Ga-PSMA-11正电子发射断层扫描/计算机断层扫描在多参数磁共振成像阴性或可疑男性中诊断临床显著前列腺癌的附加诊断价值

Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-12-06

PRIMARY2是一项多中心、两组、3期随机对照试验,计划招募660例临床怀疑临床显著前列腺癌且多参数磁共振成像PI-RADS评分为2分伴警示信号或3分的男性,随机1:1分组。试验组行盆腔PSMA PET/CT,阳性者行靶向经会阴前列腺穿刺,阴性者仅监测前列腺特异性抗原;对照组全部行模板经会阴前列腺穿刺。主要终点为随机化后6个月时避免经会阴前列腺穿刺的比例,并评估不遗漏临床显著前列腺癌。

要点

  • PRIMARY2试验评估PSMA PET/CT能否让部分男性避免经会阴前列腺穿刺而不遗漏临床显著前列腺癌。
  • 入组标准为临床怀疑临床显著前列腺癌且PI-RADS评分为2分伴警示信号或3分(PI-RADS v2)。
  • 试验组PSMA PET/CT阳性者行靶向穿刺,阴性者仅监测前列腺特异性抗原;对照组全部行模板穿刺。

核心结论

  • PRIMARY试验已显示[68Ga]Ga-PSMA-11 PET/CT与临床显著前列腺癌检测的敏感性和阴性预测值显著改善相关;PRIMARY2旨在证明加用PSMA PET/CT可使部分男性避免经会阴前列腺穿刺而不遗漏临床显著前列腺癌,并有助于对PSMA高摄取部位进行靶向穿刺。

研究设计与样本

  • 多中心、两组、3期随机对照试验,计划招募660例计划接受穿刺的参与者,按1:1比例采用置换区组随机化并按中心分层,试验注册号为NCT05154162。

主要发现

  • 该试验为方案报告,尚未报告主要结局结果。

关键数值与推荐

  • 临床显著前列腺癌定义为经会阴前列腺穿刺Gleason评分3+4(≥10%)=7分(分级组2)或更高。
  • 主要终点将在随机化后6个月时测量避免经会阴前列腺穿刺的比例,并按意向性治疗原则分析。
  • 试验组中PSMA PET/CT阳性者行靶向经会阴前列腺穿刺,阴性者仅行前列腺特异性抗原监测;对照组全部行模板经会阴前列腺穿刺。
  • 参与者随机化后将接受后续临床随访长达2年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) has an established role for the diagnosis of clinically significant prostate cancer (sPCa). The PRIMARY trial demonstrated that [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT) was associated with a significant improvement in sensitivity and negative predictive value for sPCa detection. OBJECTIVE: To demonstrate that addition of prostate-specific membrane antigen (PSMA) radioligand PET/CT will enable some men to avoid transperineal prostate biopsy without missing sPCa, and will facilitate biopsy targeting of PSMA-avid sites. DESIGN, SETTING, AND PARTICIPANTS: This multicentre, two-arm, phase 3, randomised controlled trial will recruit 660 participants scheduled to undergo biopsy. Eligible participants will have clinical suspicion of sPCa with a Prostate Imaging-Reporting and Data System (PI-RADS) score of 2 and red flags, or a PI-RADS score of 3 on mpMRI (PI-RADS v2). Participants will be randomised at a 1:1 ratio in permuted blocks stratified by centre. The trial is registered on ClinicalTrials.gov as NCT05154162. INTERVENTION: In the experimental arm, participants will undergo pelvic PSMA PET/CT. Local and central reviewers will interpret scans independently using the PRIMARY score. Participants with a positive result will undergo targeted transperineal prostate biopsies, whereas those with a negative result will undergo prostate-specific antigen monitoring alone. In the control arm, all participants undergo template transperineal prostate biopsies. Participants will be followed for subsequent clinical care for up to 2 yr after randomisation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: sPCa is defined as Gleason score 3 + 4 (≥10%) = 7 disease (grade group 2) or higher on transperineal prostate biopsy. Avoidance of transperineal prostate biopsy will be measured at 6 mo from randomisation. The primary endpoints will be analysed on an intention-to-treat basis. CONCLUSIONS: Patient enrolment began in March 2022, with recruitment expected to take 36 mo. PATIENT SUMMARY: For patients with suspected prostate cancer who have nonsuspicious or unclear MRI (magnetic resonance imaging) scan findings, a different type of scan (called PSMA PET/CT; prostate-specific membrane antigen positron emission tomography/computed tomography) may identify men who could avoid an invasive prostate biopsy. This type of scan could also help urologists in better targeting of samples from suspicious lesions during prostate biopsies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Buteau JP, Moon D, Fahey MT, et al. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol. 2023. PMID: 38061976. doi:10.1016/j.euo.2023.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。